Ocasio-Cortez confronts CEO for nearly $2K price tag on HIV drug that costs $8 in Australia

Rep. Alexandria Ocasio-CortezAlexandria Ocasio-CortezOvernight Health Care: Democrats attack after Trump revives talk of ObamaCare replacement | Cruz, Ocasio-Cortez efforts on birth control face major obstacles | CVS investing M to fight teen e-cig use Overnight Health Care: Democrats attack after Trump revives talk of ObamaCare replacement | Cruz, Ocasio-Cortez efforts on birth control face major obstacles | CVS investing M to fight teen e-cig use The Hill's Morning Report - Is US weighing military action against Iran? MORE (D-N.Y.) confronted a CEO Thursday for pricing a drug designed to reduce the risk of HIV transmission at $8 in Australia but over $1,500 in the U.S.

"You're the CEO of Gilead. Is it true that Gilead made $3 billion in profits from Truvada in 2018?" Ocasio-Cortez asked Gilead CEO Daniel O'Day.

"$3 billion in revenue," he clarified.

ADVERTISEMENT

"The current list price is $2,000 a month in the United States, correct?" she asked, referring to Truvada.

"It's $1,780 in the United States," O'Day responded.

"Why is it $8 in Australia?" Ocasio-Cortez countered.

"Truvada still has patent protection in the United States and in the rest of the world it is generic," O'Day explained, adding, "It will be generically available in the United States as of September 2020."

"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we lead and developed all the patents to create Prep and then that patent has been privatized despite the fact that the patent is owned by the public, who refused to enforce it," Ocasio-Cortez said.

“There’s no reason this should be $2,000 a month. People are dying because of it and there’s no enforceable reason for it.”

Truvada is a prophylactic treatment for HIV or AIDs that reduces the risk of infection.